Effect of Quercetin on Prophylaxis and Treatment of COVID-19
NCT ID: NCT04377789
Last Updated: 2021-02-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
447 participants
INTERVENTIONAL
2020-03-20
2020-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Effectiveness of Phytotherapy in SARS-COV2(COVID-19)
NCT04851821
Quercetin in the Prevention of Covid-19 Infection
NCT05037240
Quercetin In The Treatment Of SARS-COV 2
NCT04853199
Biological Effects of Quercetin in COPD
NCT03989271
Biological Effects of Quercetin in COPD Phase II
NCT06003270
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
non-quercetin group
Participants, who accept to enroll the study without having quercetin prophylaxis and who do not have a history of COVID-19, will be in this group.
No interventions assigned to this group
quercetin prophylaxis group
Participants, who takes a daily dose of 500mg quercetin and who not have a history of COVID-19, will be in this group.
Quercetin Prophylaxis
a daily dose of quercetin (500mg) will be taken by non-COVID-19 intervention group 1
quercetin treatment group
Participants, who takes a daily dose of 1000mg quercetin and who are proven cases for COVID-19, will be in this group.
Quercetin Treatment
a daily dose of quercetin (1000mg) will be taken by proven COVID-19 cases intervention group 2
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Quercetin Prophylaxis
a daily dose of quercetin (500mg) will be taken by non-COVID-19 intervention group 1
Quercetin Treatment
a daily dose of quercetin (1000mg) will be taken by proven COVID-19 cases intervention group 2
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* obtained informed consent
Exclusion Criteria
* genetic/chromosomal abnormalities
* any kind of sensitivity or allergy for quercetin
* history of previous hypersensitivity with quercetin
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Orbiteratec (funding)
UNKNOWN
Kanuni Sultan Suleyman Training and Research Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Hasan Onal
Professor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Kanuni Sultan Suleyman Training and Research Hospital
Istanbul, , Turkey (Türkiye)
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
KSSEAH--0058
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.